Arrecife

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating whether ultrasound-guided alcohol sclerotherapy can reduce pelvic pain and improve quality of life in women aged 18 to 45 diagnosed with ovarian endometriomas. This study compares sclerotherapy to expectant management to determine which approach better helps manage symptoms and quality of life impacts associated with this common form of endometriosis. Participants are randomly assigned to either receive ultrasound-guided alcohol sclerotherapy involving puncture and alcohol treatment of the cysts or to be managed expectantly with standard pain management if needed. The sclerotherapy procedure involves a 15-minute application of absolute ethanol followed by a wash. Both groups will be followed for six months, with assessments at baseline and 6 months post-treatment. During the study, participants will complete quality of life and pain assessments using standardized tools, provide blood and urine samples for biomarker analysis, and undergo ovarian reserve evaluations. Researchers will monitor adverse events, cyst recurrence, fertility outcomes, and healthcare costs. Pregnancy outcomes will be followed for an average of two years. The main outcome is quality of life measured at baseline and 6 months.

Researchers are comparing two sedation methods for critically ill patients on mechanical ventilation inhaled isoflurane delivered via the Sedaconda ACD-S system versus intravenous propofol. This Phase IV, low-intervention, open-label, randomized controlled trial aims to evaluate which method leads to more ventilator-free days within 28 days post-randomization. The study focuses on patients expected to need deep sedation and mechanical ventilation for over 48 hours in the intensive care unit ICU. Participants will be randomly assigned to one of two groups. One group receives inhaled isoflurane starting at 3 mLh, adjusted to reach a target sedation level without exceeding 14 mLh, guided by end tidal isoflurane concentration. Short periods with higher concentrations may be used. The other group receives intravenous propofol starting at 0.5-1 mgkgh, carefully increased to reach the target sedation without exceeding 4 mgkgh. If sedation targets are not met, a secondary hypnotic may be added in either group. During the study, participants will be monitored for ventilator-free days at 28 days, ICU-free days, time to extubation, sedation effectiveness, use of additional sedatives, and delirium incidence and duration within 28 days. Researchers will also assess mental, cognitive, and quality of life outcomes at 90 days after hospital discharge. Safety, including treatment-related adverse events and mortality up to 60 days, will be tracked. The trial includes 620 patients across multiple centers, with data collected throughout the ICU stay and follow-up periods.